Reductions in NT-proBNP concentrations were associated with sacubitril/valsartan-related benefits in the PARADIGM-HF study [8], and have been shown to be associated with reverse left ventricular remodeling during other guideline-directed medical therapies for HF [15,16]. The gene discussed is NPPB; the disease is hydrops fetalis.